Celecoxib chemical structure
Find information on thousands of medical conditions and prescription drugs.

Celebrex

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum growths polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Celecoxib is a highly selective COX-2 inhibitor and primarily inhibits this isoform of cyclooxygenase, whereas traditional NSAIDs inhibit both COX-1 and COX-2. Celecoxib is approximately 10-20 times more selective for COX-2 inhibition over COX-1. In theory, this specificity allows celecoxib and other COX-2 inhibitors to reduce inflammation (and pain) while minimizing gastrointestinal adverse drug reactions (e.g. stomach ulcers) that are common with non-selective NSAIDs. It also means that it has a reduced effect on platelet aggregation compared to traditional NSAIDs.

Adverse effects

Aside from the incidence of gastric ulceration, celecoxib exhibits a similar adverse drug reaction (ADR) profile to other NSAIDs.

Gastrointestinal ADRs

In theory the COX-2 selectivity should result in a significantly lower incidence of gastrointestinal ulceration than traditional NSAIDs. The main body of evidence touted to support this theory were the preliminary (6 month) results of the Celecoxib Long-term Arthritis Safety Study (CLASS) as published in 2000, which demonstrated a significant reduction in the incidence of gastrointestinal ulceration in those taking celecoxib versus ibuprofen or diclofenac. (Silverstein et al, 2000) The final (12 month) results from the CLASS study, however, did not indicate any advantage of celecoxib over the other NSAIDs in the study. (Malhotra, Shafiq & Pandhi, 2004)

Cardiovascular risk

The withdrawal of rofecoxib from the market in 2004 due to an increased risk of adverse cardiovascular events led to the suspicion that this was a class effect. Indeed an increased risk of heart attack and stroke was found in a National Cancer Institute study studying the use of 400-800 mg celecoxib daily for the prevention of colorectal adenoma (relative risk 2.3-3.4 vs placebo). (Solomon et al., 2005)

There is still much conjecture, however, as to whether this risk is significant for the majority of patients being treated with lower doses for osteoarthritis. The overall safety profile of celecoxib, including its cardiovascular, renal and digestive effects, will be compared to traditional anti-inflammatoris (naproxen and ibuprofen) in a randomized trial of 20,000 high risk patients that is due to begin in 2006 (PRECISION study sponsored by Pfizer)

Allergy

Celecoxib contains a sulfonamide moiety and may cause allergic reactions in those allergic to other sulfonamide-containing drugs. This is in addition to the contraindication in patients with severe allergies to other NSAIDs.

Commercial history

Celecoxib was developed by G. D. Searle & Company and marketed jointly by Searle and Pfizer under the brand name Celebrex. Searle was acquired by Pharmacia, which was then acquired by Pfizer, in part so that Pfizer could take full control of Celebrex.

Read more at Wikipedia.org


[List your site here Free!]


Celebrex And Vioxx: Are They Safer Than The Older Anti- Inflammatory Drugs? - Brief Article
From Healthfacts, 9/1/01 by Maryann Napoli

Ever since the anti-inflammatory drugs, Celebrex and Vioxx, came on the market two and a half years ago, questions have surrounded them. Do these costly drugs offer a safer alternative to other arthritis drugs? Do they have a lower rate of the gastrointestinal side effects associated with older painkillers, such as aspirin, ibuprofen, and acetaminophen? If so, is this benefit canceled by heart-related risks linked to Celebrex and Vioxx?

A new analysis of all clinical trials that had attempted to answer these questions was conducted by Debabrata Mukherjee, MD, and colleagues at the Cleveland Clinic Foundation. But before their analysis appeared in the Journal of the American Medical Association last month, a controversy erupted over the validity of the results from the largest and most important clinical trial involving Celebrex. Its manufacturer, Pharmacia, withheld long- term data, which made Celebrex appear safer than it really is.

Celebrex and Vioxx belong to a relatively new class of drugs called selective COX-2 inhibitors, which control inflammation by blocking enzymes called prostaglandins. Celebrex was the first COX-2 inhibitor to appear on the market (in 1999); Vioxx followed soon after. Both are prescribed for osteoarthritis, rheumatoid arthritis, and other chronically painful conditions.

The question of whether these COX-2 inhibitors can reduce the risk of gastric hemorrhage or ulcers is critical to justifying their high cost. These adverse effects may occur, sometimes without warning, with all drugs in a class called non-steroidal, anti-inflammatory drugs (NSAIDs), which includes aspirin, ibuprofen, acetaminophen, diclofenac, and naproxen. NSAID-induced gastrointestinal bleeding causes about 15,000 deaths and 70,000 more hospitalizations yearly. Most NSAIDs can be purchased in their low cost generic versions at a fraction of the cost of Celebrex and Vioxx. If the makers of Celebrex and Vioxx can prove their drugs reduce the likelihood of gastrointestinal damage, then insurance companies, HMOs, and Medicare would find the $85 monthly cost acceptable.

Two large clinical trials dominated the new analysis conducted by Dr. Mukherjee and colleagues. The one that produced suspect results was sponsored by Pharmacia, and they appeared to favor its drug. Celebrex reduced the rate of gastrointestinal complications without increasing the risk of "cardiovascular events" (e.g., heart attacks, stroke). This trial had randomly assigned 8,059 people with osteoarthritis to take daily doses of Celebrex, ibuprofen, or diclofenac. (All three drugs are NSAIDs.) Dr. Mukherjee and colleagues pointed out that reduced incidence of heart-related side effects could be due to the fact that the study participants were allowed to continue the low-aspirin regimen followed by many older people as a heart attack preventive.

Pharmacia released only the six-month results of its study, though the trial had lasted 13 months. When the longer-term results came to the attention of the Food and Drug Administration's advisory panel, they cast doubt on Celebrex's purported reduced incidence of gastrointestinal complications because they began to show up in the second half of the study. Ultimately, the participants taking Celebrex had the same rate of gastrointestinal side effects as those taking the two older NSAIDs. Significantly, this trial was not designed to answer the question of whether Celebrex is a more effective painkiller than the older NSAIDs..

Vioxx had its own large trial that had randomly assigned 8,076 people with rheumatoid arthritis to take either Vioxx or another NSAID, Naproxen. Unlike the Celebrex trial, the participants were not permitted to take aspirin. At the end of this trial, which lasted nine months, serious cardiovascular events had occurred in 45 patients who were taking Vioxx and in 20 of those who had been taking Naproxen. It is not known whether this difference is due to the clot-busting effect of Naproxen or a clot-causing effect of Vioxx.

The review of these large trials and other smaller studies led Dr. Mukherjee and colleagues to conclude that COX-2 inhibitors may carry a small risk of heart attack, but more long-term research is needed. Though the ads for Celebrex and Vioxx emphasize the words excellence and efficacy, neither has been proven a more effective painkiller than the older NSAIDs. People with osteoarthritis should consider the over-the-counter supplement, glucosamine, which has been proven to be an effective pain reliever in clinical trials.

--

Maryann Napoli is the associate director of the Center for Medical Consumers in New York City.

COPYRIGHT 2001 Center for Medical Consumers, Inc.
COPYRIGHT 2001 Gale Group

Return to Celebrex
Home Contact Resources Exchange Links ebay